LENSAR

LENSAR Forward P/E

The Forward P/E Ratio of LENSAR (LNSR) as of Oct 18, 2026 is -4.26. In the previous year, Forward P/E Ratio was -4.65 — a change of -8.39% (higher).

Forward P/E

-4.26

YoY

-8.39%

Last updated:

Forward P/E Ratio of LENSAR is 2025 -4.26 . Forward P/E Ratio of LENSAR was 2024 -4.65 . It decreases by -8.39% higher compared to the previous year.

The LENSAR Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-11.60 USD
Jan 1, 2019
-9.97 USD
Jan 1, 2020
-7.39 USD
Jan 1, 2021
-7.45 USD
Jan 1, 2022
-7.34 USD
Jan 1, 2023
-10.16 USD
Jan 1, 2024
-4.65 USD
Jan 1, 2025
-4.26 USD
The LENSAR Forward P/E history
YEARForward P/EYoY
-4.26-8.39%
-4.65-54.20%
-10.16+38.46%
-7.34-1.57%
-7.45+0.88%
-7.39-25.88%
-9.97-14.08%
-11.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Forward P/E Ratio of LENSAR is -4.26 in 2025.

Forward P/E Ratio of LENSAR changed from -4.65 to -4.26, representing a -8.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio LENSAR since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LENSAR

All Key Metrics — LENSAR